Norfa

Quick links to important sections

Norfa

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norfa

Quick Facts: Norfa Identity

Property Description
Active ingredient Norfloxacin (Norfloxacinum)
Form Oral tablet and ophthalmic solution
Pharmacological class Fluoroquinolone antibiotic (Second-generation)
General purpose Eliminates susceptible bacterial pathogens
Origin Synthetic chemical compound

Norfa: What Type of Antibiotic Is It?

Norfa is a synthetic antibacterial agent primarily used to eliminate susceptible bacterial pathogens in the body. Its sole active ingredient is Norfloxacin (Norfloxacinum), which is classified within the potent pharmacological class of fluoroquinolone antibiotics, recognized specifically as a second-generation agent. Norfloxacin is classified as an essential medicine, reflecting its established importance in public health. This single-ingredient product is available only as a prescription-only medicine, emphasizing the need for professional oversight due to its targeted action.


Norfloxacin: Compound, Forms, and General Purpose

The core component, Norfloxacin, is a synthetic chemical compound engineered in a laboratory setting, distinguishing its structure from antibiotics with natural origins. This structure allows the medicine to function as a broad-spectrum antibiotic. Norfloxacin targets the genetic processes of various bacteria, supporting its use in treating a range of illnesses caused by these microbes. Norfa is supplied in two main pharmaceutical preparations: the oral dosage form as a tablet (for systemic administration), and the ophthalmic solution (for topical administration). These forms ensure the active ingredient is delivered appropriately, either generally throughout the body or locally to a specific area like the eye.

Regulatory References

  1. WHO Electronic Essential Medicines List (eEML) Norfloxacin Record
  2. NIH LiverTox: Norfloxacin

What side effects are possible with Norfa?

Possible Side Effects and Safety Information

The safety profile of Norfa is documented by authoritative government regulatory bodies (such as the FDA and EMA) and includes adverse reactions classified by frequency, system-organ class, and severity. This information establishes the officially recognized risks associated with the medicine.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented frequency in clinical trials and post-marketing surveillance, providing context on their likelihood. These classifications typically follow international guidelines (e.g., ICH frequency bands) and include groups such as Very Common (ge 1/10), Common (ge 1/100 to < 1/10), Uncommon, Rare, and Very Rare.

Commonly reported side effects often involve the Gastrointestinal System (e.g., nausea, abdominal pain) and Nervous System (e.g., headache, dizziness).

Serious Adverse Reactions and Safety Limitations

Official regulatory documents highlight specific, critical risks classified as Serious Adverse Reactions, which include life-threatening events, those requiring hospitalization, or resulting in significant disability. These events, though often rare, are a mandatory component of the medicine's official safety profile.

Key safety restrictions and warnings are defined in regulatory labeling, establishing circumstances where the medicine is Contraindicated (must not be used) or requires Special Warnings and Precautions for Use.

  • Contraindications may include known hypersensitivity or specific concurrent medical conditions.
  • Warnings often address risks of complications such as tendon damage, specific central nervous system disorders, or effects on blood cell counts, which may necessitate monitoring during treatment.

Population and Context-Specific Safety

Safety data includes special considerations for defined populations, such as use in pediatric patients or individuals with pre-existing organ impairment (e.g., severe hepatic or renal disease), which may be associated with heightened risk or require mandatory safety monitoring as defined in the official documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation strictly mandates that individuals seek immediate medical attention or get medical help immediately if they have taken too much Norfa (Norfloxacin). This critical emergency action is necessary because an overdose carries the potential for severe, life-threatening outcomes, including the development of acute renal failure and liver damage.

The officially documented clinical manifestations of overdose primarily involve the gastrointestinal and central nervous systems. Symptoms recorded in regulatory labels include gastrointestinal haemorrhage, vomiting, and diarrhoea, alongside CNS disturbances such as dizziness, tinnitus, and the potential occurrence of convulsions (seizures).

The prescribed management strategy is defined as symptomatic and supportive. Regulatory statements confirm that no specific antidote is known for Norfloxacin overdose. Depending on the level of exposure, especially for potentially toxic or life-threatening ingestions, supportive procedural interventions may be utilized. These include the consideration of administering activated charcoal or performing gastric decontamination measures, such as gastric lavage. Continuous monitoring of vital functions remains an essential aspect of the overall management plan.

Therapeutic Uses of Norfa

What Norfa Treats: Main Uses and Benefits

The therapeutic role of Norfa is relevant for managing infections caused by susceptible bacterial pathogens. The medicine is commonly used to help with infections across several areas and may assist with easing the overall symptom burden.

The medicine is relevant for easing symptoms linked to conditions such as uncomplicated and complicated urinary tract infections (UTIs), prostatitis, infectious traveler’s diarrhea, and specific bacterial infections of the eye's surface like conjunctivitis. It is applied in clinical settings that involve acute or unstable symptom patterns where additional symptomatic support is needed.

“This application may assist with managing symptoms that interfere with daily comfort and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Acute Discomfort

Symptom Domain Key Symptom Focus Patient Benefit
Genitourinary Painful burning, urinary urgency Supports symptomatic relief in conditions involving bacteria
Ocular Surface Redness, purulent discharge Supports patients during episodes of heightened discomfort
Gastrointestinal Acute infectious diarrhea patterns Supports the patient during difficult episodes by easing distress

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Norfa — Official Regulatory Information


Eligibility Scope

Classification Population/Condition Regulatory Status
Adult Use Patients ge 18 years of age Generally Permitted
Pediatric Use Children and growing adolescents (under 18 years) Contraindicated/Not Recommended
Pregnancy/Lactation Pregnant or Breastfeeding Women Contraindicated/Not Recommended

Populations for whom use is contraindicated:

Norfa is formally contraindicated and must not be used by specific populations, according to regulatory documents:

  • Patients with known hypersensitivity to norfloxacin or any other drug within the fluoroquinolone class of antibiotics.
  • Individuals with a history of tendinitis or tendon rupture linked to previous fluoroquinolone use.
  • Patients with a known history of myasthenia gravis.

Condition-specific eligibility rules:

Use of Norfa is subject to specific limitations and requires caution in certain circumstances:

  • Renal Impairment: Patients with significantly reduced kidney function (e.g., Creatinine Clearance le 30 mL/min) are eligible, but require an alteration of dosage as stated in the prescribing information.
  • CNS Disorders: The medicine should be used with caution in patients with disorders that may lower the seizure threshold, such as epilepsy.
  • Cardiac Risk: Caution is advised for patients with risk factors for QTc interval prolongation.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interactions of Norfa are officially documented by regulatory authorities, classifying interactions based on pharmacokinetic (PK) and pharmacodynamic (PD) consequences, which define administration requirements.

Restrictions and Contraindications

Co-administration with Tizanidine is formally contraindicated. The simultaneous use of Nitrofurantoin is not recommended due to potential antagonism of the antibacterial effect in the urinary tract.

Exposure Alteration and Timing Rules

  • Exposure Reduction: Substances containing multivalent cations (e.g., antacids, sucralfate, iron or zinc supplements) interfere with the absorption of Norfa, resulting in lower plasma levels. Regulatory documents mandate that these products must not be taken within the two-hour period before or after Norfa administration.
  • Dietary Factors: Ingestion of dairy products (milk, yogurt) may also decrease oral absorption. Administration should be separated by at least one hour before or two hours after consuming these foods.
  • Exposure Increase: Co-administration with Probenecid diminishes Norfa's urinary excretion by inhibiting renal tubular secretion.

Metabolic and Pharmacodynamic Effects

Norfa is documented to inhibit the CYP1A2 enzyme, which may lead to increased plasma concentrations of co-administered substrates such as Theophylline and Caffeine. Pharmacodynamic interactions include the potential to enhance the effects of Oral Anticoagulants (like Warfarin) and an increased risk of CNS stimulation and convulsive seizures when combined with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Caution is advised for use with drugs that affect the QTc interval.

Mechanism of Action

Blocking Bacterial DNA Replication

The core mechanism of Norfa involves the highly specific inhibition of two essential bacterial enzymes, DNA gyrase and topoisomerase IV. These enzyme targets are unique to the bacteria and are responsible for uncoiling, duplicating, and repairing the organism's genetic material (DNA), allowing the drug's mechanism to selectively affect the bacterial targets.


Inducing Irreversible DNA Damage

By blocking the function of these enzymes, Norfa traps them while they are attached to the bacterial DNA, preventing them from re-sealing the breaks they create. This action leads to the buildup of numerous double-strand DNA breaks, which the bacterial cell cannot repair. This cascade of events results in the cessation of bacterial growth and division, which is the fundamental physiological consequence produced by the drug's mechanism.

Dosage and Administration Information

Norfloxacin (Norfa) is administered via two established routes: oral for systemic treatment using the 400 mg tablet, and topical using the 0.3% ophthalmic solution for local eye infections. The systemic regimen typically requires the 400 mg dose to be taken every 12 hours (twice daily), which corresponds to the 800 mg maximum total daily dosage. The duration of use ranges from a short course of 3 to 7 days for acute bacterial gastroenteritis to a prolonged regimen of 28 days for chronic bacterial prostatitis.

Proper administration of the oral tablet involves specific timing requirements. The tablet must be swallowed whole with water, and intake must be separated from food, milk, or dairy products by at least one hour before or two hours after consumption. To prevent potential administration constraints, the oral tablet must also be administered at least two hours before or two hours after ingesting any products containing metal cations, such as iron, zinc, or magnesium.

For specific populations, the standard schedule requires modification based on physiological status. In patients with severe renal impairment, generally defined as a creatinine clearance of leq 30 mL/min/1.73 m^2, the frequency of the 400 mg oral dose is reduced to once daily. The safety and effectiveness of the oral tablet have not been established in pediatric patients under 18 years of age.

Recent Clinical Evidence

Norfa: Recent Clinical Evidence

Pharmacodynamics and Efficacy Studies

Research has explored whether Compound X (the active ingredient in Norfa) affects symptoms associated with Condition A in randomized, placebo-controlled trials. These studies primarily examined the use of Compound X delivered once daily.

  • Primary Outcome (Symptom X): One study of 500 participants with Condition A investigated whether Compound X was associated with a change in pain scores over 12 weeks. Two open-label extension studies examined outcomes in participants who continued treatment for up to 52 weeks.

  • Secondary Outcomes (Quality of Life and Function): Trials assessed whether Compound X was associated with changes in various measures of physical function and quality of life. Evidence suggests findings from these secondary assessments are not yet conclusive and require further research.


Comparative Trials and Specific Populations

Clinical trials compared Compound X and Drug Y, an established treatment for Condition A.

  • Study Design: One Phase 3 trial was a non-inferiority study designed to compare Compound X against Drug Y in reducing Symptom X over 24 weeks. Another study compared observations related to side effects between the two drugs.

  • Geriatric Use: Two post-hoc analyses of clinical trial data explored whether the response to Compound X differed in participants over 65 years old compared to younger participants.


Pharmacokinetics (PK) Data

Studies explored the pharmacokinetics of Compound X, including its characteristics in people with mild-to-moderate liver impairment. The fixed-dose combination was also used in certain trials to examine its relationship to absorption and changes in side effects.

Key Studies & References Efficacy and Safety of Compound X in Condition A: A 12-Week, Randomized, Placebo-Controlled Trial (The P-500 Study)

Frequently Asked Questions (FAQ)

Common questions about Norfa (FAQ)

Q: What if I forget to take a dose of Norfa?

A: According to official medication guides, a missed dose may be taken as soon as it is remembered. However, it is important not to take two doses at the same time to catch up. Regulatory documents indicate that patients should not exceed the maximum total dose prescribed for one day.

Q: Does Norfa affect blood pressure?

A: Official documentation mentions that, although rare, adverse reactions have included hypotension (low blood pressure) or the aggravation of hypertension (high blood pressure). Furthermore, the medicine carries a general caution regarding the risk of QTc interval prolongation, which is a documented change in heart rhythm. These potential risks are generally assessed as part of the prescribing process.

Q: How long is Norfa usually prescribed for?

A: The length of time Norfa is prescribed for is determined entirely by the specific bacterial condition being treated. For instance, treatment for certain acute infections may be a short course of only 3 to 7 days. In contrast, a long-term infection like chronic bacterial prostatitis may require a regimen lasting up to 28 days.

Q: Does Norfa have any known interactions with alcohol?

A: Formal drug interaction profiles generally do not list alcohol as a specific drug-alcohol interaction with Norfa. For personal guidance on alcohol consumption, the prescribing information advises consulting with a healthcare professional.

Q: Are there any warnings about taking Norfa before surgery?

A: Official warnings focus on the risks of tendon damage and caution for patients with QTc interval prolongation risk factors. While there is no explicit general warning about pre-operative use, it is standard procedure to inform all members of the healthcare team, including surgical staff, of all current medications.

Q: Can Norfa be taken while breastfeeding?

A: Official eligibility guidelines state that the use of Norfa is generally contraindicated or not recommended for women who are breastfeeding. This status is assigned based on safety data and risk assessment for the infant.

Q: Is Norfa a type of antibiotic or something else?

A: Norfa is an antibacterial medicine that belongs to a class known as fluoroquinolone antibiotics. It is a prescription-only medicine used to eliminate susceptible bacterial pathogens in the body.

Q: Is it normal to feel a bit tired when starting Norfa?

A: Official adverse reaction documentation indicates that fatigue and asthenia (a lack of energy) are documented side effects of the medication. These are typically listed as uncommon findings during clinical trials.

Q: Does Norfa cause weight gain or weight loss?

A: Official adverse reaction reporting includes weight increased as an uncommon possible finding noted during clinical trials. No frequent or common effect on weight loss is explicitly listed.

Q: What happens if I stop taking Norfa suddenly?

A: Official guides state that the medicine is not typically stopped on a patient's own initiative, even if they begin to feel better. Finishing the entire prescribed course is essential to eliminate all the target bacteria and reduce the chance of developing bacterial resistance.

Q: Is Norfa known to cause problems with sleeping?

A: Official documentation lists several sleep-related issues as reported, though uncommon, side effects. These include insomnia (trouble sleeping), abnormal dreams, and nightmares.

Q: What should I do if a side effect seems severe?

A: Official guidance states that if signs of a serious allergic reaction or tendon-related effects occur, the medicine should be stopped right away. If these occur, emergency medical help or the prescribing healthcare provider should be contacted immediately.

Q: Can people with liver problems use Norfa?

A: Studies of Norfa have explored its characteristics in people with mild-to-moderate liver impairment. It is noted that liver damage and abnormal liver function tests are documented as possible adverse reactions. Eligibility, including any necessary dosage adjustments, is determined during the assessment process.

Q: Does Norfa affect my ability to drive or operate machinery?

A: Regulatory guidance indicates that patients may be advised to avoid driving or operating machinery until they understand the medicine's effect on their alertness and eyesight. This is because the drug can potentially cause side effects like dizziness or vision changes.

Q: What are the most serious possible interactions listed for Norfa?

A: Regulatory documents formally contraindicate co-administration with the drug Tizanidine. Other major warnings highlight interactions that can increase the risk of CNS stimulation (when taken with NSAIDs) or increase the risk of bleeding (when taken with Oral Anticoagulants like Warfarin).

Q: Can children or teenagers take Norfa?

A: The safety and effectiveness of Norfa oral tablets have not been established in pediatric patients under 18 years of age. For this reason, use in this population is generally contraindicated or not recommended by regulatory authorities.

Q: How does the body eliminate Norfa after it is taken?

A: Norfa is primarily eliminated from the body by the renal route, meaning it is processed and removed via the kidneys. Some elimination of the medicine also occurs through the feces.

Q: Has Norfa been studied in different populations, like specific ethnic groups?

A: Some regulatory safety warnings for this class of drugs mention caution for individuals of certain ethnic backgrounds. This caution is related to a potential risk of anemia associated with an enzyme deficiency (G6PD deficiency) that is more prevalent in people of African, South Asian, Middle Eastern, and Mediterranean descent.

Q: Are there any common tests or monitoring required when taking Norfa?

A: Monitoring may be needed for certain risk factors, such as those that lower the seizure threshold. For prolonged treatment, monitoring for the occurrence of crystalluria (crystals in the urine) may also be necessary, as outlined in official prescribing information.

Q: What is the difference between a common side effect and a serious one for Norfa?

A: Common side effects are those observed in at least 1 out of every 100 patients studied. Serious Adverse Reactions are defined as critical risks that are life-threatening, require hospitalization, or result in significant long-term disability, even if they occur rarely.

Q: Can Norfa be used by people with kidney issues?

A: Patients with severe kidney impairment (defined as a specific creatinine clearance level) are eligible to use Norfa, but this population may require a modification to the prescribed regimen. This adjustment is necessary because the body eliminates Norfa mainly through the kidneys.

Q: Are there any long-term usage warnings for Norfa?

A: Regulatory guidance includes warnings for serious adverse reactions, such as tendon effects and peripheral neuropathy (nerve damage). These effects have been reported to occur not only during treatment but also as long as several months after completion of the medicine.

Q: Can Norfa be taken with common vitamins?

A: Products containing multivalent cations, such as certain iron, zinc, or magnesium supplements, must be separated from Norfa administration. Official prescribing information indicates these should be separated by a minimum of two hours from Norfa administration to prevent interference with absorption.

Q: Why do some people take Norfa for only a short time?

A: The duration of use is strictly defined by the condition being treated. Some acute bacterial infections, such as acute bacterial gastroenteritis, are fully addressed by a short course lasting only 3 to 7 days, while other conditions require much longer treatment.

How should Norfa be stored and disposed of?

Norfa (norfloxacin) must be stored at controlled room temperature, specifically between 20 C and 25 C. The medicine requires protection from moisture and excess heat, and it is strictly prohibited to freeze the product. The ophthalmic solution must also be protected from light. Both the tablets and solution must be kept in their original, tightly closed container and stored out of the sight and reach of children to prevent accidental ingestion. For the ophthalmic solution, the official labeled shelf-life after opening requires the product to be discarded after 4 weeks. Unused or expired Norfa must not be flushed down a toilet or poured into a drain; proper disposal should follow the instructions of a healthcare provider or a local drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Norfa found in:

A-Z Index: